» Articles » PMID: 12753687

Thrombosis in End-stage Renal Disease

Overview
Journal Semin Dial
Specialty Nephrology
Date 2003 May 20
PMID 12753687
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Although renal failure has classically been associated with a bleeding tendency, thrombotic events are common among patients with end-stage renal disease (ESRD). A variety of thrombosis-favoring hematologic alterations have been demonstrated in these patients. In addition, "nontraditional" risk factors for thrombosis, such as hyperhomocysteinemia, endothelial dysfunction, inflammation, and malnutrition, are present in a significant proportion of chronic dialysis patients. Hemodialysis (HD) vascular access thrombosis, ischemic heart disease, and renal allograft thrombosis are well-recognized complications in these patients. Deep venous thrombosis and pulmonary embolism are viewed as rare in chronic dialysis patients, but recent studies suggest that this perception should be reconsidered. Several ESRD treatment factors such as recombinant erythropoietin (EPO) administration, dialyzer bioincompatibility, and calcineurin inhibitor administration may have prothrombotic effects. In this article we review the pathogenesis and clinical manifestations of thrombosis in ESRD and evaluate the evidence that chronic renal failure or its management predisposes to thrombotic events.

Citing Articles

Association of frailty and chronic limb-threatening ischemia in patients on maintenance hemodialysis: a prospective cohort study.

Hsieh M, Luo C, Cheng C, Dai L, Chen C, Chuang S Aging (Albany NY). 2024; 16(22):13676-13692.

PMID: 39733527 PMC: 11723663. DOI: 10.18632/aging.206178.


Severe Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Patients on Chronic Hemodialysis-Reconsidering the Relationship with Thrombo-Inflammation and Oxidative Stress.

Nikolovski S, Medic Brkic B, Savic Vujovic K, Cirkovic I, Jovanovic N, Reddy B Diagnostics (Basel). 2024; 14(21).

PMID: 39518373 PMC: 11544906. DOI: 10.3390/diagnostics14212406.


Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non-valvular atrial fibrillation: protocol for a prospective, randomised, open-label, blinded endpoint trial (APIDP2).

Ficheux M, Peyro-Saint-Paul L, Balayn D, Lecrux B, Brossier M, Morin A BMJ Open. 2024; 14(9):e089353.

PMID: 39306346 PMC: 11535701. DOI: 10.1136/bmjopen-2024-089353.


Anticoagulation in Chronic Kidney Disease.

Montomoli M, Candia B, Barrios A, Bernat E Drugs. 2024; 84(10):1199-1218.

PMID: 39120783 DOI: 10.1007/s40265-024-02077-6.


Incidence and Predictors of Acute Coronary Syndrome in Patients on Maintenance Hemodialysis: A Prospective Cohort Study.

Hsu J, Lee C, Chaung S, Cheng C, Dai L, Hsieh M Acta Cardiol Sin. 2024; 40(2):191-199.

PMID: 38532820 PMC: 10961640. DOI: 10.6515/ACS.202403_40(2).20231022A.